Lysozyme increases bactericidal activity of ceragenin CSA-13 against Bacillus subtilis

Introduction: Bacillus subtilis and other opportunistic bacilli are responsible for infrequent but serious infections such as post-surgery and post-traumatic endophthalmitis. Lysozyme is a natural protein found in various body fluids, exerting direct antibacterial activity and involved in modulation of the immune response in the site of inflammation. Ceragenins (CSAs) are cationic lipids based on cholic acid structure. CSA-13, the best-characterised molecule of its family, is distinct due to its broad-spectrum of antibacterial activity against aerobic and anaerobic Gram-positive and Gram-negative bacteria, as well as multidrug-resistant strains of fungi, parasites, and some viruses. Aim of the research: To assess whether a combination of lysozyme (the antibacterial enzyme present in various human body fluids) and CSA-13 (a new synthetic mimic of natural antimicrobial peptides) will display higher bactericidal activity against B. subtilis in comparison to their activity alone. Material and methods: The antimicrobial activities of lysozyme, CSA-13, and their combination were determined using a killing assay, and changes in bacterial cell morphology upon exposure to these antimicrobials were visualised by atomic force microscopy (AFM). In addition, interactions between the tested compounds were analysed using reductions in bacterial counts and determination of synergistic effects. Conclusions: The effects of combined treatment involving lysozyme and CSA-13 against B. subtilis indicate synergistic antibacterial activity that might be used in the development of new methods to combat infections caused by this genus of bacteria.

[1]  K. Majewski,et al.  Serum concentrations of antimicrobial peptide cathelicidin LL-37 in patients with bacterial lung infections , 2018, Central-European journal of immunology.

[2]  Anthony D. Kappell,et al.  Poultry and beef meat as potential seedbeds for antimicrobial resistant enterotoxigenic Bacillus species: a materializing epidemiological and potential severe health hazard , 2018, Scientific Reports.

[3]  A. Brisabois,et al.  Bacillus cereus, a serious cause of nosocomial infections: Epidemiologic and genetic survey , 2018, PloS one.

[4]  Juan Wang,et al.  Prevalence, Virulence Genes, Antimicrobial Susceptibility, and Genetic Diversity of Bacillus cereus Isolated From Pasteurized Milk in China , 2018, Front. Microbiol..

[5]  W. Kamysz,et al.  Activity of antimicrobial peptides and conventional antibiotics against superantigen positive Staphylococcus aureus isolated from patients with atopic dermatitis , 2018, Postepy dermatologii i alergologii.

[6]  Nguyen Bao Hung,et al.  Extrachromosomal expression of nat05 gene encoding an alkaline serine protease from Bacillus subtilis N05 , 2018 .

[7]  A. K. Criss,et al.  From bacterial killing to immune modulation: Recent insights into the functions of lysozyme , 2017, PLoS pathogens.

[8]  P. Savage,et al.  Anaerobic bacteria growth in the presence of cathelicidin LL-37 and selected ceragenins delivered as magnetic nanoparticles cargo , 2017, BMC Microbiology.

[9]  P. Savage,et al.  Ceragenins as Mimics of Endogenous Antimicrobial Peptides , 2017 .

[10]  K. Pogoda,et al.  Sporicidal activity of ceragenin CSA-13 against Bacillus subtilis , 2017, Scientific Reports.

[11]  K. Pogoda,et al.  Candidacidal Activity of Selected Ceragenins and Human Cathelicidin LL-37 in Experimental Settings Mimicking Infection Sites , 2016, PloS one.

[12]  H. Çam,et al.  Successful Treatment of Bacillus cereus Bacteremia in a Patient with Propionic Acidemia , 2016, Case reports in pediatrics.

[13]  V. Kandi Clinical Significance of Bacillus Species Other than Bacillus anthracis , 2016 .

[14]  A. Sotto,et al.  Bacillus cereus infection: 57 case patients and a literature review. , 2015, Medecine et maladies infectieuses.

[15]  E. Giralt,et al.  CSA-131, a ceragenin active against colistin-resistant Acinetobacter baumannii and Pseudomonas aeruginosa clinical isolates. , 2015, International journal of antimicrobial agents.

[16]  Tobias Bollenbach,et al.  Antimicrobial interactions: mechanisms and implications for drug discovery and resistance evolution. , 2015, Current opinion in microbiology.

[17]  P. Janmey,et al.  Bactericidal Activities of Cathelicidin LL-37 and Select Cationic Lipids against the Hypervirulent Pseudomonas aeruginosa Strain LESB58 , 2015, Antimicrobial Agents and Chemotherapy.

[18]  Xiaoxiang Hu,et al.  Expression of Recombinant Human Lysozyme in Egg Whites of Transgenic Hens , 2015, PloS one.

[19]  M. Azizi,et al.  Molecular Diagnosis and Characterization of Bacillus subtilis Isolated from Burn Wound in Iran , 2014 .

[20]  Bingqian Liu,et al.  Causative organisms of post-traumatic endophthalmitis: a 20-year retrospective study , 2014, BMC Ophthalmology.

[21]  P. Savage,et al.  Potential Synergy Activity of the Novel Ceragenin, CSA-13, against Carbapenem-Resistant Acinetobacter baumannii Strains Isolated from Bacteremia Patients , 2014, BioMed research international.

[22]  P. Janmey,et al.  Antibacterial activity of the human host defence peptide LL-37 and selected synthetic cationic lipids against bacteria associated with oral and upper respiratory tract infections. , 2013, The Journal of antimicrobial chemotherapy.

[23]  Min Jin Kim,et al.  Combined Bacillus licheniformis and Bacillus subtilis infection in a patient with oesophageal perforation. , 2012, Journal of medical microbiology.

[24]  P. Savage,et al.  In vitro Activities of the Novel Ceragenin CSA-13, Alone or in Combination with Colistin, Tobramycin, and Ciprofloxacin, against Pseudomonas aeruginosa Strains Isolated from Cystic Fibrosis Patients , 2012, Chemotherapy.

[25]  P. Janmey,et al.  Potential of ceragenin CSA‐13 and its mixture with pluronic F‐127 as treatment of topical bacterial infections , 2011, Journal of applied microbiology.

[26]  Y. Hirai,et al.  Bacillus cereus bacteremia outbreak due to contaminated hospital linens , 2011, European Journal of Clinical Microbiology & Infectious Diseases.

[27]  P. Janmey,et al.  Modulation of exogenous antibiotic activity by host cathelicidin LL‐37 , 2010, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[28]  R. Epand,et al.  Depolarization, Bacterial Membrane Composition, and the Antimicrobial Action of Ceragenins , 2010, Antimicrobial Agents and Chemotherapy.

[29]  J. Bader,et al.  Anti-Trypanosomatid Activity of Ceragenins , 2010, The Journal of parasitology.

[30]  E. Bottone Bacillus cereus, a Volatile Human Pathogen , 2010, Clinical Microbiology Reviews.

[31]  S. Ha,et al.  Synergistic effects of ethanol and UV radiation to reduce levels of selected foodborne pathogenic bacteria. , 2010, Journal of food protection.

[32]  Chris W. Michiels,et al.  Lysozymes in the animal kingdom , 2010, Journal of Biosciences.

[33]  C. López-Cabezas,et al.  Antibiotics in endophthalmitis: microbiological and pharmacokinetic considerations. , 2010, Current clinical pharmacology.

[34]  P. Savage,et al.  Ceragenins: a class of antiviral compounds to treat orthopox infections. , 2009, The Journal of investigative dermatology.

[35]  P. Savage,et al.  Activities of Ceragenin CSA-13 Against Established Biofilms in an In Vitro Model of Catheter Decolonization , 2009 .

[36]  A. Fouet,et al.  Biofilm Formation and Cell Surface Properties among Pathogenic and Nonpathogenic Strains of the Bacillus cereus Group , 2009, Applied and Environmental Microbiology.

[37]  Ronald N. Jones,et al.  Potential synergy activity of the novel ceragenin, CSA-13, against clinical isolates of Pseudomonas aeruginosa, including multidrug-resistant P. aeruginosa. , 2007, The Journal of antimicrobial chemotherapy.

[38]  M. Gilmore,et al.  Bacillus endophthalmitis: roles of bacterial toxins and motility during infection. , 2005, Investigative ophthalmology & visual science.

[39]  D. T. Liu,et al.  Infective endophthalmitis caused by Bacillus cereus after cataract extraction surgery. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[40]  P. Savage,et al.  Correlation of the antibacterial activities of cationic peptide antibiotics and cationic steroid antibiotics. , 2002, Journal of medicinal chemistry.

[41]  M. Welsh,et al.  Synergistic and additive killing by antimicrobial factors found in human airway surface liquid. , 2000, American journal of physiology. Lung cellular and molecular physiology.

[42]  C. Foster,et al.  Bacillus-induced endophthalmitis: new series of 10 cases and review of the literature. , 1990, The British journal of ophthalmology.

[43]  D. Shlaes,et al.  Serious Infections Caused by Bacillus Species , 1987, Medicine.

[44]  R. Guillard,et al.  Comparison between the folding of reduced hen egg white lysozyme and that of reduced human milk lysozyme. , 1982, Biochemistry.